Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.
Avinger Price Performance
Shares of AVGR Stock opened at $1.70 on Tuesday. The stock's fifty day moving average is $1.56 and its 200-day moving average is $3.44. The company has a debt-to-equity ratio of 1.24, a quick ratio of 3.78 and a current ratio of 4.67. The stock has a market capitalization of $9.66 million, a PE ratio of -0.30 and a beta of 1.68. Avinger has a 52 week low of $1.40 and a 52 week high of $20.80.
Avinger (NASDAQ:AVGR - Get Rating) last announced its earnings results on Tuesday, May 10th. The medical device company reported ($2.33) EPS for the quarter, missing the consensus estimate of ($1.21) by ($1.12). The business had revenue of $1.89 million for the quarter, compared to the consensus estimate of $1.89 million. Avinger had a negative return on equity of 143.44% and a negative net margin of 185.01%. During the same quarter in the previous year, the company posted ($1.40) EPS. Equities research analysts expect that Avinger will post -4.97 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages have weighed in on AVGR. B. Riley lowered their price target on Avinger from $11.00 to $9.00 in a research report on Wednesday, May 11th. StockNews.com assumed coverage on Avinger in a research report on Wednesday, August 3rd. They issued a "sell" rating on the stock.